Masitinib
Masitinib is an anticancer chemotherapeutic and anti-inflammatory compound used in veterinary medicine. Masitinib inhibits c-Kit and PDGFR, increasing survival time in the treatment of mast cell tumors and other cancers. In vitro, masitinib increases levels of caspases 3 and 7, inducing apoptosis. Masitinib also decreases airway inflammation and edema in feline allergic asthma models and also decreases the patient-rated severity of multiple sclerosis in clinical settings. Masitinib also exhibits potential efficacy against Alzheimer’s disease when given as an adjunct therapy, slowing cognitive decline.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18941534
| Cas No. |
790299-79-5 |
|---|---|
| Purity |
≥98% |
| Formula |
C28H30N6OS |
| Formula Wt. |
498.64 |
| IUPAC Name |
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide |
| Appearance |
Gray to off white powder |
Smrkovski OA, Essick L, Rohrbach BW, et al. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet Comp Oncol. 2013 Jul 12. [Epub ahead of print]. PMID: 23845124.
Fahey CE, Milner RJ, Kow K, et al. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anticancer Drugs. 2013 Jun;24(5):519-26. PMID: 23466652.
Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012 Jun 12;12:36. PMID: 22691628.
Lee-Fowler TM, Guntur V, Dodam J, et al. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369-74. PMID: 22487554.
Cadot P, Hensel P, Bensignor E, et al. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Vet Dermatol. 2011 Dec;22(6):554-64. PMID: 21668810.
Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimers disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. PMID: 21504563.
